| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO and CFO
1 company
Steven A Shallcross is CEO and CFO at TOVX. Steven A Shallcross's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $46K at current prices.
Historically, Steven A Shallcross's trades have earned a below-average insider score of 37/100 across 8 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -46.0%.
Net of sales, the TOVX filings show accumulation of 340,000 shares.
Steven A Shallcross has 22 Form 4 filings on record from June 2015 to January 2026, across 2 companies: CEO and CFO at Theriva Biologics (TOVX), 2015–2026; Director at Twin Vee PowerCats (VEEE), 2021.
The 22 reported transactions were 13 option or other derivative awards and 9 open-market purchases.
Counted by filing, the open-market trades come to 9 purchases worth about $205K and no sales.
The largest open-market purchase was 100,000 shares of TOVX at an average $0.44 on December 29, 2022, about $44K. Twelve months later TOVX was down 7%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 14,000 | $0.69 | $9,703.40 | +5.9% | -26.7% | -61.9% | |
| Jun 6, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 26,000 | $0.63 | $16,452.80 | +12.4% | -19.6% | -56.4% | |
| Feb 10, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 25,000 | $1.04 | $26,075.00 | +13.5% | -33.8% | -49.5% | |
| Feb 2, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 25,000 | $0.94 | $23,512.50 | +15.6% | -31.9% | -45.7% | |
| Jan 25, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 25,000 | $0.87 | $21,825.00 | +18.5% | -19.3% | -50.9% | |
| Jan 20, 2023 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 25,000 | $0.75 | $18,705.00 | +22.7% | -7.1% | -45.7% | |
| Dec 29, 2022 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 100,000 | $0.44 | $43,700.00 | +1,000% | +47.8% | -6.5% | |
| May 10, 2021 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 50,000 | $0.49 | $24,595.00 | +100.0% | +7.2% | -51.0% | |
| Aug 23, 2019 | TOVX Theriva Biologics, Inc. | CEO and CFO | Buy | 50,000 | $0.42 | $20,785.00 | New | - | - |